mRNA vaccine for liver cancer patients awaiting transplant
Part of Cancer, Digestive system clinical trials.
This trial tests an mRNA vaccine for people with liver cancer who are waiting for a liver transplant. The vaccine is given to help control the cancer while they wait.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have hepatocellular carcinoma (liver cancer) that meets the criteria for a liver transplant
- You are waiting for a liver transplant and need treatment to control the cancer during the wait
- You are positive for hepatitis B (HBsAg)
- You are able to carry out daily activities with little to no help (ECOG score 0-2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) combined with a PD-1 inhibitor to prevent liver cancer from coming back after surgery. It is for people with early-stage liver cancer who have a high risk of recurrence.
This trial tests a DNA-based vaccine called NWRD06 to lower the risk of liver cancer returning after a curative surgery or ablation. It is for people with a specific protein on their cancer cells and good liver function.
This trial tests whether continuing antiviral therapy after surgery for hepatitis B-related liver cancer can improve outcomes. It focuses on patients with early-stage disease, good liver function, and no prior cancer treatments other than surgery or ablation.
This trial tests a new mRNA vaccine for people with advanced liver cancer that has returned or spread after other treatments. The vaccine aims to help your immune system fight the cancer more effectively.
This trial tests a personalized mRNA vaccine made from your tumor's unique genetic markers. It is for people with advanced liver cancer who have not yet received any treatment.
This Phase 1 study tests a lab-made immune cell treatment that targets hepatitis B (HBV)–related liver cancer. It may help by directing the body’s immune system to attack the cancer, while carefully checking safety.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.